Orchard is a London-based gene therapy company at the forefront of developing innovative treatments for patients living with rare genetic diseases, including neurometabolic and neurodegenerative disorders and primary immune deficiencies. The company’s approach harnesses the unique power of a patient’s own genetically modified blood stem cells, to correct the underlying cause of a genetic disease permanently using a single administration. With multiple products in the pipeline, Orchard has recently launched Libmeldy in the EU, to treat children with metachromatic leukodystrophy.
Professor Gaspar has been actively engaged in and has taken a leading role in scientific and clinical investigations of ex vivo autologous gene therapies since the early 1990s. His contributions have been instrumental in effectively translating gene therapies from the confines of the laboratory to real-world clinical applications.
We invite you to join us as we delve into the inspiring journey of Orchard Therapeutics from laboratory to the clinic and explore the profound impact of their life-changing gene therapy treatments.